glycyrrhizic acid has been researched along with Fatty Liver, Nonalcoholic in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (72.73) | 24.3611 |
| 2020's | 3 (27.27) | 2.80 |
| Authors | Studies |
|---|---|
| Bian, H; Xia, M; Xu, Y; Yang, X | 1 |
| Ji, HF; Li, XY; Shen, L; Wang, S | 1 |
| Gao, X; Guo, S; Liu, A; Shi, L; Wang, Q; Wen, A; Zhang, S; Zhang, T; Zhang, Y | 1 |
| Duan, X; Huo, X; Liu, K; Liu, Z; Ma, X; Meng, Q; Sun, H; Sun, P; Sun, X; Wang, C | 1 |
| Chu, AZ; Hu, YH; Li, YW; Zhu, CL; Zhu, TT | 1 |
| Cao, L; Gonzalez, FJ; Hao, H; Krausz, KW; Li, G; Takahashi, S; Wang, G; Wang, H; Wang, Q; Yagai, T; Yan, T | 1 |
| Cao, H; Guo, Z; Li, Y; Li, Z; Liu, T; Wang, B; Wang, S; Xie, R; Yan, C; Zhang, Y | 1 |
| Antoniv, A; Kanovska, L; Khukhlina, O; Mandryk, O; Smandych, V | 1 |
| Chen, YH; Hu, P; Peng, ML; Ren, H; Zhan, Z | 1 |
| Rino, Y; Yamamoto, N; Yukawa, N | 1 |
| Duan, X; Liu, K; Liu, Z; Meng, Q; Sun, H; Sun, P; Sun, X; Wang, C; Yang, X | 1 |
2 review(s) available for glycyrrhizic acid and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Metabolic dysfunction associated fatty liver disease and coronavirus disease 2019: clinical relationship and current management.
Topics: Age Factors; Angiotensin-Converting Enzyme 2; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; COVID-19; COVID-19 Drug Treatment; Cytokines; Dipeptides; Gene Expression Regulation; Glucose; Glycyrrhizic Acid; Humans; Hypoxia; Liver; Lung; Non-alcoholic Fatty Liver Disease; Receptors, Virus; SARS-CoV-2; Severity of Illness Index | 2021 |
Does herbal medicine reduce the risk of hepatocellular carcinoma?
Topics: Animals; Anti-Inflammatory Agents; Benzimidazoles; Carcinoma, Hepatocellular; Clinical Trials as Topic; Cysteine; Drug Combinations; Drugs, Chinese Herbal; Fatty Liver; Fluorenes; Glycine; Glycyrrhetinic Acid; Glycyrrhizic Acid; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Neoplasms; Non-alcoholic Fatty Liver Disease; Phytotherapy; Plant Preparations; Sofosbuvir; Tablets | 2015 |
9 other study(ies) available for glycyrrhizic acid and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Modulation of gut microbiota by glycyrrhizic acid may contribute to its anti-NAFLD effect in rats fed a high-fat diet.
Topics: Animals; Diet, High-Fat; Flavonoids; Gastrointestinal Microbiome; Glycyrrhizic Acid; Liver; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Plant Extracts; Rats | 2022 |
Glycyrrhetinic acid attenuates disturbed vitamin a metabolism in non-alcoholic fatty liver disease through AKR1B10.
Topics: Aldo-Keto Reductases; Animals; Diet, High-Fat; Disease Models, Animal; Enzyme Inhibitors; Glycyrrhetinic Acid; Glycyrrhizic Acid; Hep G2 Cells; Humans; Hydrolysis; Kinetics; Liver; Male; Mice, Inbred C57BL; Molecular Docking Simulation; Non-alcoholic Fatty Liver Disease; Vitamin A | 2020 |
Protective effects of glycyrrhizic acid against non-alcoholic fatty liver disease in mice.
Topics: Animals; Body Weight; Cytoprotection; Diet, High-Fat; Fatty Acids; Gene Expression Regulation; Gluconeogenesis; Glucose Tolerance Test; Glycogen; Glycyrrhizic Acid; Insulin Resistance; Liver; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Organ Size; Receptors, Cytoplasmic and Nuclear; Triglycerides | 2017 |
[Clinical efficacy of compound glycyrrhizin tablets in the treatment of children with nonalcoholic fatty liver disease].
Topics: Adolescent; Child; Female; Glycyrrhizic Acid; Humans; Male; Non-alcoholic Fatty Liver Disease; Tablets | 2017 |
Glycyrrhizin Alleviates Nonalcoholic Steatohepatitis via Modulating Bile Acids and Meta-Inflammation.
Topics: Animals; Anti-Inflammatory Agents; Bile Acids and Salts; Glycyrrhizic Acid; Hep G2 Cells; Humans; Inflammation; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Random Allocation; RAW 264.7 Cells | 2018 |
Diammonium Glycyrrhizinate Protects against Nonalcoholic Fatty Liver Disease in Mice through Modulation of Gut Microbiota and Restoration of Intestinal Barrier.
Topics: Animals; Anti-Inflammatory Agents; Gastrointestinal Microbiome; Glycyrrhizic Acid; Immunohistochemistry; Intestinal Mucosa; Intestines; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Real-Time Polymerase Chain Reaction | 2018 |
EFFECTIVENESS OF NONALCOHOLIC STEATOHEPATITIS CORRECTION ON THE BAСKGROUND OF OBESITY WITH CONCOMITANT CHRONIC KIDNEY DISEASE.
Topics: Administration, Oral; Anti-Inflammatory Agents; Cysteine; Drug Administration Schedule; Drug Combinations; Extracellular Matrix; Glycine; Glycyrrhizic Acid; Humans; Injections, Intravenous; Non-alcoholic Fatty Liver Disease; Obesity; Renal Insufficiency, Chronic; Treatment Outcome | 2018 |
[A new attempt with lipoprotein lipase agonists in the treatment of nonalcoholic steatohepatitis].
Topics: Bezafibrate; Biopsy; Carboxylic Acids; Case-Control Studies; Computational Biology; Enzyme Activators; Gemfibrozil; Glycyrrhizic Acid; Humans; Lipid Metabolism; Lipoprotein Lipase; Non-alcoholic Fatty Liver Disease; Oligonucleotide Array Sequence Analysis; Scavenger Receptors, Class E | 2019 |
Protective effects of glycyrrhizic acid from edible botanical glycyrrhiza glabra against non-alcoholic steatohepatitis in mice.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Biomarkers; Diet; Fatty Acids; Glycyrrhiza; Glycyrrhizic Acid; Inflammation; Lipid Metabolism; Lipogenesis; Liver; Male; Methionine; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Triglycerides | 2016 |